Scarica l'app Stockscreener
4.34
4.83%
0.20
Dopo l'orario di chiusura:
4.45
0.11
+2.53%
Precedente Chiudi:
$4.14
Aprire:
$4.16
Volume 24 ore:
49,115
Relative Volume:
0.34
Capitalizzazione di mercato:
$19.66M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-0.1331
EPS:
-32.6
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
+5.60%
1M Prestazione:
+9.05%
6M Prestazione:
-14.90%
1 anno Prestazione:
+13.73%
Intervallo 1D:
$4.05
$4.35
Intervallo di 1 settimana:
$3.97
$4.35
Portata 52W:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.34 | 19.66M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView
Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan
Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com
Cingulate Inc. expands equity plan following stockholder approval - Investing.com
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus
Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
McCann Joburg acquires a healthcare marketing company - Bizcommunity
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus
Cingulate receives FDA meeting feedback on ADHD drug - Investing.com
Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks
Cingulate Inc. Reports First Quarter 2025 Financial Results - GlobeNewswire
27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks
CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus
Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks
Cingulate Announces Positive Top-Line Results from - GlobeNewswire
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - The Manila Times
Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World
Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail
Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance
Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals
CING: 2024 Financial and Operational Results - Yahoo Finance
Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks
Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire
Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):